MARKET WIREStocktwits • 20h ago
TECX: Tectonic Therapeutic Inc. Latest Stock Price, Analysis, News and Trading IdeasStocktwits report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
Why TECX Stock dropped -4.04% Today — RQD Quant Desk Flash
$18.98 -4.04% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $18.81
Tectonic Therapeutic Inc. (TECX) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $386.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on TECX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is TECX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Tectonic Therapeutic Inc. (NASDAQ: TECX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $18.98 (-4.04% 1D, market cap $386.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does TECX compare to ZURA and PROK in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TECX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ZURA (Zura Bio Limited (Class A)) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $389.2M) and PROK (ProKidney Corp. (Class A)) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $391.6M). Among the 5-stock peer group, TECX leads on earnings multiple (N/A) while TECX leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for TECX?
▼
Per TECX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001681087), Tectonic Therapeutic Inc. generated $235.3M in revenue (+44.9% YoY), -$74.15B in net income, and -$60.3M in free cash flow against $261.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $18.81 (-0.92%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TECX)Realized 20D OHLCV Swing Band: ±10.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY TECX SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (27% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$21.31+2.4% Next Q
38
Q2 (-2Q)Grade E$21.83-6.8% Next Q
35
Q3 (-1Q)Grade E$20.34-6.7% Next Q
33
CurrentGrade E$18.98-9.6% Hist 90D α
30
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TECX Turnaround Squeeze
While TECX currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($25.33) and Max Pain ($19.93) forces dealer call-delta covering toward $41.51.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TECX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TECX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TECX Stock dropped -4.04% Today — RQD Quant Desk Flash
Tectonic Therapeutic Inc. (TECX) dropped -4.04% to $18.98, trading at 14% of its 52-week range ($15.52 – $39.53). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 14% of its 52-week range ($15.52 – $39.53) with RSI-14 at 33.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.5% around $18.98 (no active unusual options sweep snapshot on file).
- ▸Primary SEC / Cross-Feed Trigger: TECX Exhibits 2.75x True Net Liquidity Elasticity as Fed-TGA-RRP Prints $5,746B
Live TECX Headlines & Catalysts
MARKET WIRESeeking Alpha • 23h ago
Tectonic Therapeutic, Inc. (TECX) Presents at CureHHT 16thHHT International Scientific Conference - SlideshowSeeking Alpha report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Tectonic Therapeutic, Inc. Estimates – NASDAQ:TECXTradingView report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMoomoo • 1d ago
Piper Sandler Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $76Moomoo report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com • 1d ago
UBS initiates Tectonic Therapeutics stock with neutral ratingInvesting.com report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
TECX Q3'26 Earnings: revenue estimate is 0 USDTradingView report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
TRex Bio (TRXB) Stock Price, News & AnalysisStock Titan report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
Most Active Stocks Today: U.S. MarketTradingKey report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 22d ago
UBS Initiates Coverage On Tectonic Therapeutic with Neutral Rating, Announces Price Target of $26UBS analyst Alice Nettleton initiates coverage on Tectonic Therapeutic (NASDAQ:TECX) with a Neutral rating and announces Price Target of $26.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TECX)
- ✓Walkthrough of TECX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TECX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -35.99%▼ SUPPORT BREAKDOWN
2026-11-03O $20.50H $20.50L $18.98C $18.98VOL 146.3K
RES: $37.97SUP: $27.64SMA50: $25.33SMA200: $28.09
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TECX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TECX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TECX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TECX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TECX)
Health Care Rank #794 of 1016
⚔️ ZURA vs TECX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TECX vs. ZURA, PROK, TRXB, AUTL)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Tectonic Therapeutic Inc. (TECX) ranks #794 by composite RQD confidence (30/100, grade E) and #479 by equity capitalization ($386.7M). Within this direct 5-issuer industry benchmark cohort, TECX leads on earnings valuation at N/A trailing P/E, while TECX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TRXB currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with TECX at 30/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TECX
ACTIVE
Tectonic Therapeutic Inc. | E | 30/100 | — | — | -35.0% | -4.04% | $386.7M | Benchmark Subject |
| ZURA Zura Bio Limited (Class A) | E | 29/100 | — | — | -35.0% | -2.47% | $389.2M | /zura-vs-tecx → |
| PROK ProKidney Corp. (Class A) | D- | 35/100 | — | — | -35.0% | -13.51% | $391.6M | /prok-vs-tecx → |
| TRXB TRex Bio Inc. | D | 48/100 | — | — | — | -0.73% | $377.1M | /trxb-vs-tecx → |
| AUTL Autolus Therapeutics plc | E | 21/100 | — | -27.8% | -35.0% | -6.58% | $404.6M | /autl-vs-tecx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001681087In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tectonic Therapeutic Inc. (TECX) reported GAAP revenue of $235.3M (+44.9% vs. FY2024 revenue of $162.4M , and +88.2% cumulative change since FY2023) , GAAP net income of -$74.15B, operating cash flow of -$60.1M, and free cash flow of -$60.3M (-1.8% YoY). On the balance sheet, TECX closed FY2025 with $261.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $235.3M | -$74.15B | -$60.1M | -$60.3M | $261.0M | — |
| FY2024 (FY) | 2024-12-31 | $162.4M | -$57.98B | -$59.1M | -$59.2M | $152.9M | — |
| FY2023 (FY) | 2023-12-31 | $125.0M | -$42.82B | -$40.7M | -$40.7M | — | — |
3. TECX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TECX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Tectonic Therapeutic Inc. (NASDAQ: TECX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $18.98 (-4.04% 1D, market cap $386.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.
How does TECX compare to ZURA and PROK in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TECX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ZURA (Zura Bio Limited (Class A)) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $389.2M) and PROK (ProKidney Corp. (Class A)) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $391.6M). Among the 5-stock peer group, TECX leads on earnings multiple (N/A) while TECX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TECX?
Per TECX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001681087), Tectonic Therapeutic Inc. generated $235.3M in revenue (+44.9% YoY), -$74.15B in net income, and -$60.3M in free cash flow against $261.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TECX trading relative to its 50-day, 200-day, and 52-week technical levels?
TECX last traded at $18.98 (-4.04% on volume of 183,887 shares), positioning the stock -25.07% below its 50-day simple moving average ($25.33) and -32.43% below its 200-day simple moving average ($28.09). Across its 52-week range of $15.52 to $39.53, TECX sits at the 14.4% percentile with a 14-day RSI of 33.9 (NEUTRAL RANGE) and an implied next-earnings move of ±10.5% ($16.99 to $20.97).
ROARABLE RATING BRIEF • RQD 30/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
TECX — Tectonic Therapeutic Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:37:00Z
1. Roarable Rating Brief: What This Means to a Prospective Investor
TECX scores 30 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -35%; FCF yield -15.04%); Whale 13F Flow at 3/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 6/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).
For a prospective investor, the weakest pillars are the cash engine and the ownership-flow signals. The balance sheet pillar is the relative bright spot, though a Piotroski F-Score of 2/9 is still weak. Upside drivers would need to come from a shift in the cash engine, which the data does not yet show. The valuation tradeoff is that the stock trades at a $400.8M market cap while reporting no revenue in the periods provided, so the market price depends heavily on expectations outside the reported figures.
2. Business Model, Unit Margins & SEC Financial Trajectory
Tectonic Therapeutic Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The company has a market capitalization of $0.4B. Per the financials, reported revenue is — in each of FY 2023, FY 2024, and FY 2025. Customer base and product details are —
Every reported period shows zero revenue and operating losses, and the gross, operating, and net margins in market data are all 0%. ROIC is -35%. The Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Cash increased from $141.2M in FY 2024 to $253.8M in FY 2025 while operating losses widened, and debt is reported as N/A, so the balance sheet posture should be read alongside the stated cash-burn figures.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case: Cash on hand rose to $253.8M in FY 2025 while the balance sheet pillar scores 10/20 with an Altman Z of 2.5 and Debt/Equity of 0.5. With Fundamental Cash Engine at 8/20 (ROIC -35.0%, FCF yield -15.04%) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $15.52 – $39.53 52-week range.
- 🐻 Primary Bear Case: ROIC of -35% and FCF yield of -15.04% show a business that continues to consume capital with zero reported revenue across FY 2023 through FY 2025. Investors must weigh current valuation against — operating margins and a 1.00 macro beta if sector demand softens.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies are — The liquidity signal indicates heightened sensitivity to macro liquidity conditions, meaning a tightening in net liquidity could amplify downside pressure on the stock, per the graph's bearish direction. Specific sector correlations and 2nd-order bottlenecks are —
- Key Question #1: What revenue, if any, does the company generate, and when is it expected to begin?
- Key Question #2: What drives the reported net loss of -$74.15B in FY 2025 relative to the operating loss of -$84.0M?
- Key Question #3: What is the debt position, given that debt is reported as N/A across all periods?
TECX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Tectonic Therapeutic Inc. (TECX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Stocktwits • 20h ago
TECX: Tectonic Therapeutic Inc. Latest Stock Price, Analysis, News and Trading Ideas Stocktwits report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 23h ago
Tectonic Therapeutic, Inc. (TECX) Presents at CureHHT 16thHHT International Scientific Conference - Slideshow Seeking Alpha report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Tectonic Therapeutic, Inc. Estimates – NASDAQ:TECX TradingView report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 1d ago
Piper Sandler Maintains Tectonic Therapeutic(TECX.US) With Buy Rating, Maintains Target Price $76 Moomoo report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 1d ago
UBS initiates Tectonic Therapeutics stock with neutral rating Investing.com report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
TECX Q3'26 Earnings: revenue estimate is 0 USD TradingView report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
TRex Bio (TRXB) Stock Price, News & Analysis Stock Titan report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
Most Active Stocks Today: U.S. Market TradingKey report covering Tectonic Therapeutic Inc. (TECX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
TECX Bull vs. Bear Conversation Board — What's Your Call at $18.98?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TECX 🐻 33% BEARISH CONVICTION
QU QuantViper Systematic Momentum Desk 🐂 BULLISH
🎯 Target: $25.71 (+30.0%)
📌 Pinned Debate Cash on hand rose to $253.8M in FY 2025 while the balance sheet pillar scores 10/20 with an Altman Z of 2.5 and Debt/Equity of 0.5.
Here is why I am bullish on TECX here at $19.78: Cash on hand rose to $253.8M in FY 2025 while the balance sheet pillar scores 10/20 with an Altman Z of 2.5 and Debt/Equity of 0.5.. Compare TECX's 0.0% operating margin and -35.0% ROIC against the rest of Biotechnology: Biological Products (No Diagnostic Substances). As long as cash conversion holds up, dips toward $18.79 are getting bought.
SectorRotator 🐂 BULL
@QuantViper Agree on the RQD 30/100 quality, though with 1.0 beta I'm scaling in with half-size at $19.78 and keeping dry powder in case we test $18.40.
RE RedlineAuditor Accounting Quality Watch 🐻 BEARISH
🎯 Target: $15.82 (-20.0%)
Spot @ $19.78 ROIC of -35% and FCF yield of -15.04% show a business that continues to consume capital with zero reported revenue across FY 2023 throu
Careful chasing TECX at $19.78. ROIC of -35% and FCF yield of -15.04% show a business that continues to consume capital with zero reported revenue across FY 2023 through FY 2025.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $15.82 on multiple compression.